Fulcrum Therapeutics, Inc. (FULC) stock
Close on Nov 12, 2026Market cap $280.77MP/E –Yield –
Fulcrum Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$65.24M. At the latest close the market valued the company at $280.77M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $280.77M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.93
- Dividend yield
- –
- Free cash flow yield
- -23.24%
Fundamentals
- Revenue
- $0
- Net income
- -$76.34M
- EPS, diluted
- -$1.18
- Free cash flow
- -$65.24M
- Book value per share
- $3.96
- Diluted shares
- 76M
Trading
- Previous close
- $3.74
- Open
- $3.74
- Day's range
- $3.68 – $3.74
- Volume
- 2,139,196
- Average volume (20 days)
- 1,300,025
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.56
- 52-week range
- $2.83 – $15.74
- RSI (14 days)
- 52.4
- Volatility (1 year)
- 92.3%
- Relative volume
- 0.58×
- WACC
- 12.7%
On 1 of our idea list: Net-nets
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | FULC | S&P 500 | Difference | FULC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.9% | -2.7% | +0.8 pts | ||
| 3 months | -1.1% | -1.7% | +0.7 pts | ||
| Year to date | -67.5% | +11.9% | −79.4 pts | ||
| 1 year | -56.0% | +12.0% | −68.0 pts | ||
| 3 years | +5.1% | +78.2% | −73.0 pts | +1.7% | +21.2% |
| 5 years | -80.0% | +73.2% | −153.3 pts | -27.6% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fulcrum Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Results
- Results
- Results
About Fulcrum Therapeutics
Pharmaceutical Preparations
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies to treat genetically defined rare diseases. Its lead product candidate is pociredir, an investigational oral drug engineered to stimulate fetal hemoglobin production to address the biological causes of sickle cell disease. The company also investigates drug candidates for conditions such as prostate cancer and beta-thalassemia through cellular target discovery methods. Fulcrum Therapeutics operates as a single business focused on benign hematology and genetic conditions, targeting affected patients and the hematologists who provide their clinical care.
Company profile, executives and historyFulcrum Therapeutics stock: common questions
What is Fulcrum Therapeutics's stock price?
FULC closed at $3.68 on Nov 12, 2026, down 1.60% on the day. Over the past 52 weeks it traded between $2.83 and $15.74.
What is Fulcrum Therapeutics's market cap?
Fulcrum Therapeutics was worth $280.77M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is FULC's P/E ratio?
Fulcrum Therapeutics lost money over fiscal 2025 (diluted EPS -$1.18), so it has no meaningful P/E ratio.
How much revenue does Fulcrum Therapeutics make?
Fulcrum Therapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Fulcrum Therapeutics pay a dividend?
No. Fulcrum Therapeutics has not paid a cash dividend over the last twelve months.
How has FULC stock performed over the past year?
Including dividends, FULC returned -56.0% over the past year, against +12.0% for the S&P 500.
How many FULC shares are sold short?
6M shares were sold short at the latest FINRA report, 12.92% of the float, or 4.8 days of average trading volume.
Who are Fulcrum Therapeutics's competitors?
Companies most similar to Fulcrum Therapeutics by business, industry and size include FHTX, AGIO, KURA, KROS, WVE.
See a number that looks wrong?